Vericel (VCEL)
(Real Time Quote from BATS)
$50.42 USD
+2.07 (4.28%)
Updated May 20, 2024 02:30 PM ET
3-Hold of 5 3
D Value A Growth B Momentum B VGM
Brokerage Reports
Vericel Corporation [VCEL]
Reports for Purchase
Showing records 21 - 40 ( 42 total )
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Burn Franchise Growth Adds to The Momentum; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Strong Growth From Both Segments; Higher $65 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Strong 4Q20 Telegraphs Growth Potential in 2021 and Beyond; Higher $60 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
4Q20 Preliminary Results Project Growth in 2021; Higher $44 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
MACI Recovery Bodes Well for 2021; Burn Franchise Growth in Sight; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Analyst Day Provides More Clarity on Commercialization Strategy; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Strong Preliminary 3Q20 Topline Telegraphs Recovery and Growth; Higher $26 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Expect NexoBrid Approval in June 2021; Vericel to Host an Investor Day in October
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Signs of Recovery Telegraphs a Better 2H20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Encouraging Recovery Trajectory; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
NexoBrid BLA Filed as Planned; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Strong 1Q20 Revenues, Growth Expected Post COVID-19 Impact in 2Q20; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Strong Finish Carries Momentum Into 2020 and Beyond; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
BARDA Procurement Bodes Well for Nexobrid BLA Approval
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Sales Force Expansion Likely to Sustain Growth Momentum; Higher $21 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Company: Vericel Corporation
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: NAPODANO J